Gadolinium released from MR contrast agents is deposited in brain tumors: In situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy

Acta Radiologica

Volumn 51, Issue 10, 2010, Pages 1126-1136

  Xia, Daniel ^a   Davis, Richard L ^a   Crawford, Judith A ^a   Abraham, Jerrold L ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Complications; MR imaging; Pathology; Tissue characterization

Indexed keywords

ABNORMAL TISSUES; BEFORE AND AFTER; BLOOD-BRAIN BARRIER; BRAIN TUMORS; COMPLICATIONS; CONTRAST-ENHANCED MR; ELECTRONIC RECORDS; ENERGY DISPERSIVE X RAY SPECTROSCOPY; EXACT TESTS; IN-SITU; MR CONTRAST AGENTS; MR IMAGING; MRI CONTRAST AGENTS; RENAL DISEASE; RENAL FAILURE; SCANNING ELECTRONS; SEM/EDS; STATISTICAL SIGNIFICANCE; TISSUE CHARACTERIZATION;

BIOPSY; DEPOSITS; DISEASES; HISTOLOGY; MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHOSPHORUS; SCANNING ELECTRON MICROSCOPY; TUMORS; X RAY SPECTROSCOPY;

GADOLINIUM;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; BRAIN; BRAIN TUMOR; CHILD; FEMALE; HUMAN; IMAGE ENHANCEMENT; INFANT; MALE; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCANNING ELECTRON MICROSCOPY; SPECTROMETRY; ULTRASTRUCTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BRAIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; RETROSPECTIVE STUDIES; SPECTROMETRY, X-RAY EMISSION; YOUNG ADULT;

EID: 78349291543     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841851.2010.515614     Document Type: Article

References (32)

1. Spencer A, Wilson S, Harpur E. Gadolinium chloride toxicity in the mouse. Hum Exp Toxicol 1998;17:633-7.
2. Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245-55.
3. Behra-Miellet J, Gressier B, Brunet C, Dine T, Luyckx M, Cazin M, et al. Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 1996;18:437-42.
4. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
5. Thomsen HS. Is NSF only the tip of the "gadolinium toxicity" iceberg? J Magn Reson Imaging 2008;28:284-6.
6. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-62.
7. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73-6.
8. Abraham JL, Edward M. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Am J Roentgenol 2009;193: W354; author reply W355.
9. Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-93.
10. Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu-Alfa AK, et al. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. J Magn Reson Imaging 2009;30:1284-8.
11. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
12. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-4.
13. Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008;158:607-10.
14. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2007;158:273-80.
15. Thakral C, Abraham JL. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin. J Electron Microsc (Tokyo) 2007;56:181-7.
16. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007;2:199-205.
17. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
18. George SJ, Webb SM, Abraham JL, Cramer S P. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010 Jun. 19 [E-pub ahead of print].
19. Essig M, Weber MA, von Tengg-Kobligk H, Knopp M V, Yuh WT, Giesel FL. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 2006;17:89-106.
20. SAS Institute. JMP. 1989-2007; Version 7.
21. Alves FC, Donato P, Sherry AD, Zaheer A, Zhang S, Lubag AJ, et al. Silencing of phosphonate-gadolinium magnetic resonance imaging contrast by hydroxyapatite binding. Invest Radiol 2003;38:750-60.
22. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-76.
23. Abraham JL, Chandra S, Thakral C, Abraham JM. SIMS imaging of gadolinium isotopes in tissue from nephrogenic systemic fibrosis patients: release of free Gd from magnetic resonance imaging contrast agents. App Surf Sci 2008;255:1181-4.
24. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73.
25. White G W, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (Pro-Hance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272-8.
26. Maramattom B V, Manno EM, Wijdicks EF, Lindell e P. Gadolinium encephalopathy in a patient with renal failure. Neurology 2005;64:1276-8.
27. Ray DE, Holton JL, Nolan CC, Cavanagh JB, Harpur ES. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. Am J Neuroradiol 1998;19:1455-62.
28. Ray DE, Cavanagh JB, Nolan CC, Williams SC. Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats. Am J Neuroradiol 1996;17:365-73.
29. Li L, Gao FQ, Zhang B, Luo BN, Yang ZY, Zhao J. Overdosage of intrathecal gadolinium and neurological response. Clin Radiol 2008;63:1063-8.
30. Roman-Goldstein SM, Barnett PA, McCormick CI, Ball MJ, Ramsey F, Neuwelt EA. Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. Am J Neuroradiol 1991;12:885-90.
31. Mizgerd J P, Molina RM, Stearns RC, Brain JD, Warner AE. Gadolinium induces macrophage apoptosis. J Leukoc Biol 1996;59:189-95.
32. Strande JL, Routhu K V, Hsu A, Nicolosi AC, Baker JE. Gadolinium decreases inflammation related to myocardial ischemia and reperfusion injury. J Inflamm (Lond) 2009;6:34.